
| Location | Burlington, MA |
Position Summary
MBX is seeking a Formulation Development Scientist to join the Drug Product team and help advance our peptide therapeutic pipeline. Reporting to the Associate Director, Formulation Development, this role provides hands on technical support across drug product formulation, process development, and manufacturing from early development through clinical and commercial readiness.
The Formulation Development Scientist will collaboratively support formulation development activities in lab as well as partnering closely with internal CMC, Regulatory, Program teams, and external CDMOs and CROs. This role is ideal for a motivated scientist who thrives in a fast paced, collaborative environment and enjoys solving complex technical challenges to enable successful drug development.
The successful candidate will contribute to the design, optimization, and execution of robust, scalable drug product formulation; review data generated at CDMOs; support technology transfer and GMP manufacturing. This individual will also play a key role in preparing regulatory ready CMC documentation and supporting global regulatory submissions.This is a high impact opportunity to shape drug product strategy, influence development decisions, and help bring innovative peptide therapies to patients.
Key Responsibilities
Education & Qualifications
Travel
You will be expected to travel periodically based on the needs of the business to the extent requested by the Company, including attendance at Together Weeks, Together Days, and functional meetings as requested by the Company.
Company Overview:
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
EEO Statement:
MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.

